Synthesis of Gd-DOTA-BMTP and its application in gadolinium neutron capture therapy for osteosarcoma Authors: Aoyun Yan, Liming Zhu, Bowen Luo, Xiaoxi Pang, JiaLin Qin, Liang Dong, Ye Zhao, Ni Chen Published: 2026 ABSTRACT AbstractOsteosarcoma (OS) represents one of the most prevalent primary malignant bone tumors affecting children and adolescents. Despite the establishment of standard treatment protocols (surgery and chemotherapy) in the 1980s, patient survival rates remain suboptimal. This underscores the critical need for the development and investigation of novel therapeutic technologies. Neutron capture therapy (NCT), an emerging precision therapeutic modality, selectively targets and eradicates tumor cells while minimizing damage to surrounding healthy tissues. In this study, we developed a novel agent, Gd-DOTA-BMTP, by attaching the cyclic nonapeptide c(CGRRAGGSC) to DOTA, followed by chelation of gadolinium (Gd) to the DOTA-BMTP. This peptide can specifically targeting osteosarcoma and binding to IL-11Rα, a cell surface receptor. Gd-DOTA-BMTP demonstrated excellent targeting specificity and a favorable biosafety profile. Furthermore, rigorous in vitro and in vivo evaluations confirmed the efficacy of Gd-DOTA-BMTP in suppressing osteosarcoma, specifically by enhancing radiosensitivity to neutron irradiation. Collectively, these findings suggest that Gd-DOTA-BMTP holds potential as a candidate for Gadolinium Neutron Capture Therapy (Gd-NCT) of osteosarcoma.Graphical abstractAn overview of the process of neutron capture therapy mediated by Gd-DOTA-BMTPSupplementary InformationThe online version contains supplementary material available at https://doi.org/10.1007/s00432-026-06537-2. Introduction Osteosarcoma is a highly aggressive primary tumor predominantly affecting children and adolescents (Ivan et al. 2025). The introduction of standard therapy (surgery combined with chemotherapy) in the 1980s elevated the 5-year survival. However, the majority of osteosarcoma cases arise in anatomically complex locations, rendering surgical intervention challenging and causing the 5-year survival rate to plummet to 20–30% (Moukengue et al. 2022). Limited progress in treatment modalities over the past four decades highlights the urgent need for novel therapeutic approaches. Neutron capture therapy (NCT), a specialized and targeted cancer treatment strategy based on nuclear reactions. Boron Neutron Capture Therapy (BNCT) represent one of the mainstream treatment methods today. Based on the nuclear reaction between (epi)thermal neutrons and boron-10, BNCT utilizes the generating alpha particles and recoiling lithium-7 nuclei with high linear energy transfer(LET) that exert cytotoxic effects on tumor cells. Given the extremely short range of these particles—approximately equivalent to the diameter of a single cell, BNCT can precise destruction of tumor cells while sparing the surrounding normal tissues from damage (Barth et al. 2018a; Jin et al. 2022; Mechetin and Zharkov 2023). Notably, BNCT also exerts a potent cytotoxic effect on hypoxic and quiescent cells, a unique advantage that endows it with considerable potential in the treatment of refractory malignancies, including recurrent and advanced tumors (Miyatake et al. 2016). Nevertheless, the clinical translation of BNCT has been hampered by the suboptimal tumor selectivity low targeting efficiency, rapid in vivo clearance of existing boron delivery agents represented by boronophenylalanine (BPA) and sodium borocaptate (BSH), have been approved for clinical use. These limitations result in insufficient boron accumulation in tumor cells and tissues to reach the effective therapeutic concentration, ultimately leading to suboptimal clinical outcomes. Gadolinium neutron capture therapy (Gd-NCT) represents an alternative approach based on the non-radioactive isotope 157Gd. Upon (epi)thermal neutron absorption, 157Gd undergoes a nuclear reaction, producing excited 158Gd*, which decays by emitting gamma rays and a cascade of Auger and internal conversion electrons (30–250 eV) (Hagiwara et al. 2019; Ho et al. 2022). Compared to B-10, Gd-157 offers a 66-fold higher neutron capture cross-section (Lee et al. 2022). Another advantage of Gd-NCT is the ability to monitor the agent biodistribution through the body via magnetic resonance imaging (MRI), thus allowing a theranostic approach to cancer treatment (Verwilst et al. 2015). Studies indicate strong Gd uptake in gliomas, osteosarcoma, and hepatic tumors, positioning it as a promising therapeutic avenue (Abello et al. 2019; Kiviniemi et al. 2019; Luo et al. 2025). However, achieving precise tumor targeting and localized dose deposition remains a critical challenge for Gd-NCT in osteosarcoma treatment. Interleukin-11 (IL-11) is a pleiotropic cytokine belonging to the IL-6 family that exerts its biological functions through binding to a specific receptor complex composed of IL-11 receptor α (IL-11Rα) and the common signal transducer gp130, which then activates downstream signaling pathways, mainly JAK/STAT3, as well as PI3K/Akt and MAPK/ERK cascades. Research has shown that the IL-11 receptor α subunit (IL-11Rα) is highly expressed in primary osteosarcoma lesions and pulmonary metastases. The expression of IL-11Rα correlates positively with tumor progression and poor patient prognosis, while being almost undetectable in normal bone and lung tissues (Lewis et al. 2009; Lewis 2014; Lokau et al. 2020; Sottnik and Thamm 2010). Therefore, IL-11Rα represents a potential therapeutic target for osteosarcoma. The bone metastasis-targeting peptidomimetic BMTP (CGRRAGGSC), designed to target bone metastases, binds specifically to IL-11Rα, induces receptor internalization, and facilitates targeted delivery to osteosarcoma cells (Huang et al. 2012; Jiang et al. 2022; Lewis et al. 2017; Lewis 2014). Therefore, in this study, we synthesized Gd-DOTA-BMTP by attaching the cyclic nonapeptide c(CGRRAGGSC) to 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), followed by chelation of gadolinium (Gd) to the DOTA-BMTP. We further assessed the specific binding affinity of Gd-DOTA-BMTP to osteosarcoma cells. Moreover, we rigorously evaluated the tumor-suppressive efficacy of the agent when combined with neutron irradiation. Our findings demonstrated that Gd-DOTA-BMTP significantly increased radiosensitivity, implying its possible application in Gd-NCT for the treatment of osteosarcoma. Materials and methods Cell culture The UMR106 rat osteosarcoma cell line (purchased from ATCC via Shanghai Fuxiang Biotechnology Co., Ltd.) was cultured in DMEM medium (61965059, Gibco) supplemented with 10% (v/v) fetal bovine serum (FBS, 10270-106, Gibco) and 1% (v/v) penicillin–streptomycin (15140122, Gibco). Cells were maintained at 37 °C in a humidified atmosphere containing 5% CO₂ and 95% air. Animal model Orthotopic Osteosarcoma Model: Four-week-old Sprague Dawley (SD) rats were anesthetized, and the tibial injection site was disinfected with 70% ethanol. The ankle joint was externally rotated to align the tibia and fibula, and the knee was flexed to visualize the proximal tibial plateau through the skin. A needle was inserted percutaneously, drilled through the tibial plateau towards the distal tibia (confirmed by loss of resistance), and 30 μL of osteosarcoma cell suspension (5 × 106 cells in PBS) was slowly injected. Following syringe withdrawal, the injection site was compressed with a cotton swab for 30 s. Rats were monitored for 4 weeks to establish the model. Subcutaneous Transplantable Osteosarcoma Model in Nude Mice: A 50 μL suspension of osteosarcoma cells (3 × 106 cells in PBS) was injected subcutaneously into the right flank of 6-week-old female nude mice. When tumor volume reached 60–100 mm3, therapeutic agents were administered intravenously 4–6 h prior to neutron irradiation. Tumor growth was monitored every two days using calipers until a volume of 1500 mm3 was attained. Tumor volume was calculated as 0.5 × length × width2. All rats and mice (4–6 weeks old) were obtained from the Nanjing Model Animal Center (Nanjing, China). All animal procedures were approved by the Animal Ethics Committee of Anhui Medical University (LLSC20232209) and conducted in accordance with institutional guidelines. Irradiation conditions X-ray irradiation was performed using a 225 keV linear accelerator (SHARP100; Raycision Medical Technology Co., Ltd) at a dose rate of 2 Gy/min, with a source-to-surface distance of 100 cm. Neutron irradiation was conducted using the Hefei Neutron Source (Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, China) at a neutron flux of 1.0 × 109 n cm⁻2 s⁻1, delivering a total absorbed dose of 1.5 Gy. Synthesis of the targeted agents Synthesis of Gd-DOTA-BMTP Gd-DOTA-BMTP peptide was synthesized using standard Fmoc solid-phase peptide synthesis (SPPS) protocols. Amino acid coupling reactions were performed using the HOBt-DIC system, and deprotection was carried out with 20% piperidine in DMF, monitored by the ninhydrin test. Upon completion of peptide chain assembly, DOTA was conjugated to the N-terminus, and the peptide was subsequently cleaved from the resin. Post-synthetic procedures included disulfide bond formation and Gd3⁺ chelation. The resulting product was purified by high-performance liquid chromatography (HPLC) and characterized by mass spectrometry, the obtained Gd-DOTA-BMTP was indeed isolated as a trifluoroacetic acid (TFA) salt. Synthesis of Gd-DOTA-BMTP-FITC Synthesis and Characterization of Gd-DOTA-BMTP -FITC, for fluorescent tracking, a Lysine (Lys) residue was specifically incorporated into the peptide sequence during SPPS to provide a site-specific attachment point for fluorescent labeling. The target peptide was synthesized on a 2-Cl(Trt)-Cl resin using standard Fmoc solid-phase peptide synthesis. Following backbone assembly, the side-chain Dde protecting group was removed with hydrazine hydrate, and the resin was subsequently reacted with FITC and DIEA in the dark for fluorescent labeling. The labeled peptide was cleaved from the resin and globally deprotected using a TFA-based cocktail, followed by precipitation with cold diethyl ether. The crude peptide was initially purified by semi-preparative HPLC, subjected to oxidation to form the disulfide bond, and re-purified. Finally, the oxidized peptide was complexed with GdCl₃ in an aqueous acetonitrile solution at room temperature. The final product, Gd-DOTA-BMTP-FITC, was purified by HPLC, lyophilized, and fully characterized using analytical HPLC and LC–MS. Synthesis of 131I-Gd-DOTA-BMTP The 131I-Gd-DOTA-BMTP was synthesized using the standard Chloramine-T oxidation method. To facilitate efficient radioiodination, a tyrosine (Tyr) residue was specifically incorporated into the peptide sequence during the SPPS process. Briefly, 10–50 μg of BMTP in 0.1 M PBS (pH 7.4) was mixed with 1–5 mCi of Na131I in an ice bath. The reaction was initiated by the rapid addition of 10–20 μg Chloramine-T. After vortexing for 30–60 s on ice, the oxidation was immediately quenched by adding sodium metabisulfite Na2S2O5. The radiolabeled complex was purified using a Sep-Pak C18 cartridge (or HPLC) to remove unreacted 131I and impurities. The radiochemical purity (RCP) was determined to be > 90% by instant thin-layer chromatography (ITLC-SG) using 85% methanol/water as the mobile phase. The final product was formulated in PBS, filtered through a 0.22 μm membrane, and stored at 4 °C in the dark until further use. Peptide synthesis was commissioned to Anhui Guoping Pharmaceutical Co., Ltd. The overall synthetic yield of the final Gd-DOTA-BMTP product, calculated from the initial resin loading, was 45%. The complete chemical structures of Gd-DOTA-BMTP-FITC and 131I-Gd-DOTA-BMTP, illustrating the specific conjugation sites on the Lys and Tyr residues, are provided in Supplementary Figure 1A and 1B, respectively. Cell Counting Kit-8 (CCK-8) Assay UMR106 cells were seeded in 96-well plates at a density of 2 × 103 cells/well and incubated with specified concentrations of Gd-DOTA-BMTP for 24 or 48 h. Subsequently, 100 μL of complete medium containing 10% (v/v) CCK-8 solution (BS350C, Biosharp) was added to each well. After incubation at 37 °C in the dark for 2 h, absorbance was measured at 450 nm using a microplate reader (PE Enspire, PerkinElmer). Colony formation assay UMR106 cells were seeded in 60-mm culture dishes at 500 cells/dish. After 4 h of incubation with Gd-DOTA-BMTP, the medium was aspirated, cells were gently washed twice with PBS, and fresh complete medium was added. Cells were then irradiated with either X-rays (6 Gy) or neutrons (1.5 Gy). Following irradiation, cells were cultured for 8 days to allow colony formation. Colonies were fixed with a methanol:acetic acid (9:1, v/v) mixture, stained with crystal violet, washed with PBS, air-dried inverted, and counted against a transparent background. Cell immunofluorescence UMR106 cells were seeded on sterile glass coverslips in 12-well plates and incubated overnight at 37 °C, 5% CO₂ for adherence. Cells were fixed with 4% paraformaldehyde (PFA) for 30 min, permeabilized with 0.1% Triton X-100 in PBS for 10 min, and washed three times with PBS. Non-specific binding was blocked with 5% BSA in PBS for 1 h. Cells were then incubated overnight at 4 °C with primary antibodies against IL-11Rα (10264-1-AP, Proteintech) and γ-H2AX (9718, Cell Signaling Technology). After washing, cells were incubated with Alexa Fluor 594- or Alexa Fluor 488-conjugated secondary antibodies for 1 h at room temperature in the dark. Nuclei were counterstained with DAPI for 5 min. Coverslips were mounted with anti-fade mounting medium, and images were acquired using a confocal fluorescence microscope. Fluorescence intensity was analyzed using ImageJ software. Flow cytometry UMR106 cells were incubated with 10 μg/mL Gd-DOTA-BMTP-FITC for 4 h, washed twice with PBS, trypsinized, centrifuged, and resuspended in 300 μL PBS. The cell suspension was filtered through a 200-mesh cell strainer into flow cytometry tubes. Analysis was performed on a flow cytometer (CytoFLEX, Beckman Coulter) using 488 nm excitation. Data were processed using FlowJo V10 software. Western blot Cells were lysed on ice using RIPA lysis buffer (P0013B, Beyotime). Lysates were centrifuged, and supernatants were collected. Protein concentration was determined using a BCA assay kit. Equal amounts of protein were separated by SDS-PAGE and transferred to PVDF membranes. Membranes were blocked with 5% skim milk powder (EZ66608B40, BioFroxx) dissolved in TBST for 1 h at room temperature, then probed overnight at 4 °C with primary antibodies against IL-11Rα (10264-1-AP, Proteintech) and γ-H2AX (9718, Cell Signaling Technology). After washing with TBST, membranes were incubated with HRP-conjugated secondary antibodies for 1 h at room temperature. Protein bands were visualized using an ECL kit (P10200, NCM) and imaged using a ChemiScope 6000 system. Band intensity was quantified using ImageJ software. Animal imaging and Gd-DOTA-BMTP biodistribution For SPECT/CT imaging, adult SD rats received an intravenous injection of approximately 300 μL of 131I-labeled BMTP(0.5 mCi). During the imaging procedure, rats were anesthetized with isoflurane (3–4% for induction and 1.5–2% for maintenance) in 100% oxygen at a flow rate of 1–2 L/min. Animals were placed on a thermostatic heating pad to maintain body temperature at 37 °C, and respiration was continuously monitored. Whole-body scans were acquired at 1, 2, 4, 6, and 12 h post-injection. For MRI, approximately 300 μL of Gd-DOTA-BMTP solution (25 mg/kg) was injected intravenously into the tail vein. MRI scans were performed at 1, 2, 4, 6, and 12 h after administration. At the time point corresponding to maximal gadolinium accumulation within tumors (determined by MRI), animals were euthanized. Muscle, Bone, Blood, Heart, Liver, Spleen, Lung, Kidney and Tumor were harvested, freeze-dried, and weighed. Samples were digested in PTFE vessels containing 1 mL of HNO₃ and 0.5 mL of HCl using microwave-assisted digestion. The digests were diluted to a final volume of 5 mL with ultrapure water, and Gd content was quantified by inductively coupled plasma mass spectrometry (ICP-MS). Magnetic resonance imaging (MRI) was performed independently using a high-field 9.4 T animal MRI scanner (United Imaging Healthcare, Shanghai, China). The dynamic in vivo radionuclide imaging was conducted using a dedicated animal micro-SPECT/CT scanner (RAYSOLUTION Healthcare Co., Ltd., Hefei, China). Monitoring of biodistribution dynamics The biodistribution dynamics was based on MRI. To determine the absolute quantitative biodistribution of Gd-DOTA-BMTP, SD rats were intravenously (i.v.) injected with the actual Gd-DOTA-BMTP probe via the tail vein at a dose of 25 mg/kg. Three rats were included at each observation time point. At 4 h and 24 h post-injection, the animals were euthanized. Organs as well as the tumors were carefully harvested, washed with PBS, weighed, and fully digested in concentrated nitric acid. The absolute gadolinium (Gd) content in each tissue sample was subsequently quantified utilizing an inductively coupled plasma mass spectrometry (ICP-MS) system. Finally, the quantitative biodistribution data were calculated and expressed as the percentage of the injected dose per gram of tissue (%ID/g). Biosafety of Gd-DOTA-BMTP SD rats were acclimatized for at least 1 week prior to experiments. Cardiac blood samples were collected 1 day before, 3 days post, and 7 days post Gd-DOTA-BMTP injection. Blood was centrifuged at 12,000 rpm for 15 min at 4 °C, and the serum was collected. Serum levels of aspartate aminotransferase (AST, C010-2-1, Nanjing Jiancheng), alanine aminotransferase (ALT, C009-2–1, Nanjing Jiancheng), total bilirubin (TBIL, C019-1–1, Nanjing Jiancheng), blood urea nitrogen (BUN, ab83362, Nanjing Jiancheng), and creatinine (CRE, ab65340, Nanjing Jiancheng) were measured according to the kit manufacturer's instructions using a microplate reader. Data were processed using Excel and statistically analyzed/graphed using GraphPad Prism. Statistical analysis Data are presented as the mean ± standard deviation (SD). Intergroup comparisons were performed using one-way analysis of variance (ANOVA) followed by post-hoc t-tests. Statistical analyses were conducted using GraphPad Prism 9.5 and Microsoft Excel 2013. A P-value less than 0.05 was considered statistically significant. Study approval All animal experiments were conducted in strict accordance with the animal experimental protocol approved by the Animal Experimentation Center of Anhui Medical University (approval number: LLSC20232209). Results Synthesis and purity verification of Gd-DOTA-BMTP The synthesis of Gd-DOTA-BMTP was successfully accomplished (Fig. 1A). Strict control over the chemical synthesis process, reactant stoichiometry, and reaction conditions ensured the successful preparation of this target compound. The purified DOTA-BMTP peptide was characterized by LRMS in positive ion mode (ESI +), yielding an m/z value of 1250.10, which was in close agreement with the theoretical value of 1250.40 (Fig. 1B). HPLC analysis revealed a chemical purity of 99.10% for the DOTA-BMTP peptide (Fig. 1C). After chelation with Gd, mass spectrometry analysis confirmed the successful incorporation of Gd, as evidenced by the expected mass shift. The measured molecular weight (1404.40) closely matched the theoretical value (1404.68), confirming successful synthesis of high-purity Gd-DOTA-BMTP (Fig. 1D). HPLC analysis confirmed a purity of 98.18% for Gd-DOTA-BMTP (Fig. 1E). These non-covalent interactions involved the coordination of Gd ions and the carbonyl oxygen atoms of the DOTA ester group. The results are shown in Supplementary Figure 1C. Next, we performed immunofluorescence (IF) staining on the tissue sections obtained from the mouse subcutaneous tumor model. As shown in Fig. 1F, extensive and intense specific fluorescence signals corresponding to IL-11Rα (green fluorescence) were clearly observed throughout the tumor parenchyma. The overlay with DAPI-stained nuclei (blue) further confirmed that the receptors were abundantly expressed on the cancer cells. This robust in vivo expression provides biological rationale for the subsequent binding of Gd-DOTA-BMTP. Therefore, the in vitro stability of the compound was comprehensively assessed under three representative temperatures: 4 °C, room temperature (RT), and 37 °C. As illustrated in Supplementary Figure 1D-F, the targeted complex exhibited remarkable stability across all tested environments.Fig. 1Synthesis and physicochemical characterization of Gd-DOTA-BMTP. A Schematic illustration of the synthetic route for Gd-DOTA-BMTP. B Low-resolution mass spectrometry (LRMS) spectrum of DOTA-BMTP. C HPLC chromatogram of DOTA-BMTP. D LRMS spectrum of the Gd-DOTA-BMTP, confirming successful gadolinium chelation. E HPLC chromatogram of purified Gd-DOTA-BMTP. F Representative immunofluorescence images validating IL-11Rα expression in mouse tumor tissue sections Synthesis and physicochemical characterization of Gd-DOTA-BMTP. A Schematic illustration of the synthetic route for Gd-DOTA-BMTP. B Low-resolution mass spectrometry (LRMS) spectrum of DOTA-BMTP. C HPLC chromatogram of DOTA-BMTP. D LRMS spectrum of the Gd-DOTA-BMTP, confirming successful gadolinium chelation. E HPLC chromatogram of purified Gd-DOTA-BMTP. F Representative immunofluorescence images validating IL-11Rα expression in mouse tumor tissue sections Cell viability and cellular uptake assays of Gd-DOTA-BMTP To determine the appropriate working concentration for Gd-DOTA-BMTP, we first assessed the cytotoxicity of Gd-DOTA-BMTP using the CCK-8 assay. CCK-8 assay results demonstrated that the drug exhibited no cytotoxicity against UMR106 cells when the administered concentration did not exceed 10 μg/mL at both 24 or 48 h post coincubation (Fig. 2A), indicating that this concentration is suitable for subsequent functional experiments without causing non-specific cell damage. Then the UMR106 cells were pre-incubated with 5 μg/mL or 10 μg/mL of Gd-DOTA-BMTP for 4 h to facilitate polypeptide-IL-11Rα binding. WB analysis with an anti-IL-11Rα antibody revealed that higher Gd-DOTA-BMTP concentrations correlated with reduced IL-11Rα band intensity, indicating effective binding of 10 μg/mL Gd-DOTA-BMTP to cell-surface IL-11Rα in UMR106 cells (Fig. 2B, C). Upon specific binding of Gd-DOTA-BMTP to IL-11Rα on the cell membrane, the receptor-ligand complex triggers receptor-mediated endocytosis. A significant portion of the internalized receptors may be sorted into lysosomes for degradation rather than being recycled back to the cell surface, leading to a down-regulation of the total IL-11Rα protein level detected in the assay.Fig. 2The binding of Gd-DOTA-BMTP to cell-surface receptors was verified. A Cell viability of UMR106 osteosarcoma cells following incubation with Gd-DOTA-BMTP at indicated concentrations for 24 and 48 h, Measured by CCK-8 assay. B, C Indirect Assessment of Gd-DOTA-BMTP Binding to the Cell-Surface Receptor IL-11α by WB. Representative blots (B) and quantitative analysis (C) are shown. D, E Immunofluorescence microscopy images visualizing the cellular uptake of Gd-DOTA-BMTP-FITC. Representative images (D) and quantitative analysis (E) are shown. F Quantitative analysis of Gd-DOTA-BMTP-FITC uptake efficiency measured by flow cytometry at the indicated concentrations. Data are presented as mean ± SD (n = 3). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, ns, no significant The binding of Gd-DOTA-BMTP to cell-surface receptors was verified. A Cell viability of UMR106 osteosarcoma cells following incubation with Gd-DOTA-BMTP at indicated concentrations for 24 and 48 h, Measured by CCK-8 assay. B, C Indirect Assessment of Gd-DOTA-BMTP Binding to the Cell-Surface Receptor IL-11α by WB. Representative blots (B) and quantitative analysis (C) are shown. D, E Immunofluorescence microscopy images visualizing the cellular uptake of Gd-DOTA-BMTP-FITC. Representative images (D) and quantitative analysis (E) are shown. F Quantitative analysis of Gd-DOTA-BMTP-FITC uptake efficiency measured by flow cytometry at the indicated concentrations. Data are presented as mean ± SD (n = 3). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, ns, no significant Subsequently, to directly visualize the binding of the synthetic polypeptide to IL-11Rα, the polypeptide was conjugated to fluorescein isothiocyanate (FITC) groups. As expected, we observed that the number of cells exhibiting green fluorescence increased with rising concentrations of the synthetic polypeptide, confirming significant cellular targeting and uptake (Fig. 2D, E). Meanwhile, Flow cytometry further confirmed cellular uptake, as evidenced by a distinct peak shift in cells incubated with Gd-DOTA-BMTP-FITC compared to control cells (Fig. 2F). Therefore, 10 μg/mL of Gd-DOTA-BMTP was selected as the optimal concentration for subsequent cellular experiments. Gadolinium neutron capture therapy of Gd-DOTA-BMTP on osteosarcoma cells To investigate the effectiveness of Gd-DOTA-BMTP in vitro, UMR-106 osteosarcoma cells were pre-incubated with 10 μg/mL Gd-DOTA-BMTP for 4 h before neutron irradiation. Subsequently, we performed a clonogenic survival assay to detect UMR106 cell survival. The cells suffering pre-incubation with Gd-DOTA-BMTP and subsequent neutron irradiation showed the lowest colony formation rate (Fig. 3A, B). Western blot analysis also revealed an upregulation of the phosphorylation levels of γ-H2AX following pre-incubation with Gd-DOTA-BMTP and subsequent neutron radiation (Fig. 3C, D). Consistent with these findings, immunofluorescence analysis revealed the highest intensity of γ-H2AX foci, which co-localized with DAPI-stained nuclei, in the Gd-DOTA-BMTP + Neutron group (Fig. 3E, F). These results collectively demonstrated that Gd-DOTA-BMTP-mediated GdNCT confers cytotoxicity upon osteosarcoma cells.Fig. 3Gd-DOTA-BMTP effectively induced neutron capture therapy (NCT) for osteosarcoma. A, B Clonogenic survival assay demonstrating the tumor cell-killing effect. Representative images of colonies (A) and the calculated survival fraction (B) reveal a marked reduction in proliferative capacity in cells treated with Gd-DOTA-BMTP prior to neutron irradiation. C, D Western blot analysis of the expression level ofγ-H2AX in UMR-106 cells. Cells were treated with Gd-DOTA-BMTP followed by neutron irradiation. Representative blots (C) and quantitative analysis of protein expression (D) show significantly elevated levels in the combination group compared to controls. E, F Immunofluorescence microscopy visualizing the formation of γ-H2AX foci (red) within cell nuclei (counterstained with DAPI, blue). Representative images (E) and quantitative analysis (F) are shown. Data are presented as mean ± SD(n = 3). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, ns, no significant Gd-DOTA-BMTP effectively induced neutron capture therapy (NCT) for osteosarcoma. A, B Clonogenic survival assay demonstrating the tumor cell-killing effect. Representative images of colonies (A) and the calculated survival fraction (B) reveal a marked reduction in proliferative capacity in cells treated with Gd-DOTA-BMTP prior to neutron irradiation. C, D Western blot analysis of the expression level ofγ-H2AX in UMR-106 cells. Cells were treated with Gd-DOTA-BMTP followed by neutron irradiation. Representative blots (C) and quantitative analysis of protein expression (D) show significantly elevated levels in the combination group compared to controls. E, F Immunofluorescence microscopy visualizing the formation of γ-H2AX foci (red) within cell nuclei (counterstained with DAPI, blue). Representative images (E) and quantitative analysis (F) are shown. Data are presented as mean ± SD(n = 3). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, ns, no significant Radiosensitizing effect of Gd-DOTA-BMTP on osteosarcoma cells Gadolinium (Gd) possesses a high mass energy absorption coefficient, which enables a marked increase in radiation deposition within the radiotherapy target volume. Building on these observations, the targeted binding and cellular internalization of Gd-DOTA-BMTP in osteosarcoma cells would be expected to confer significant X-ray radiosensitization effects. So, to further investigate whether Gd-DOTA-BMTP can potentiate X-ray-induced cytotoxicity under conventional radiotherapy, UMR106 cells were incubated with 10 μg/mL Gd-DOTA-BMTP for 4 h and subsequently exposed to 225 keV/6 Gy X-ray. The clonogenic assay confirmed a significant suppression of colony formation in the Gd-DOTA-BMTP + X-ray group compared to controls (Fig. 4A, B). Consistent with this growth inhibition, molecular analysis revealed intensified DNA damage. Western blot analysis showed a marked increase in γ-H2AX expression in the group treated with Gd-DOTA-BMTP + X-ray compared to the Control group and the group treated with X-ray alone (Fig. 4C, D). Immunofluorescence analysis revealed the highest mean fluorescence intensity of γ-H2AX foci in the Gd-DOTA-BMTP + X-ray group after irradiation (Fig. 4E, F). Collectively, these findings demonstrate that Gd-DOTA-BMTP significantly sensitizes osteosarcoma cells to X-ray irradiation, thereby exacerbating radiation-induced damage in vitro.Fig. 4Radiosensitizing effect of Gd-DOTA-BMTP on osteosarcoma cells under X-ray irradiation. A, B Clonogenic survival assay assessing long-term proliferative capacity. Representative images of colonies (A) and the calculated survival fraction (B) show marked growth suppression in cells treated with Gd-DOTA-BMTP prior to irradiation. C, D Western blot analysis ofγ-H2AX expression in UMR-106 cells. Cells were treated with Gd-DOTA-BMTP followed by X-ray irradiation (6 Gy). Representative blots (C) and quantitative analysis of protein levels (D) demonstrate significantly increased DNA damage in the combination group compared to controls. E, F Immunofluorescence microscopy visualizing the formation ofγ-H2AX foci (red) within cell nuclei (counterstained with DAPI, blue). Representative images (E) and quantitative analysis (F) are shown. Data are presented as mean ± SD (n = 3). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, ns, no significant Radiosensitizing effect of Gd-DOTA-BMTP on osteosarcoma cells under X-ray irradiation. A, B Clonogenic survival assay assessing long-term proliferative capacity. Representative images of colonies (A) and the calculated survival fraction (B) show marked growth suppression in cells treated with Gd-DOTA-BMTP prior to irradiation. C, D Western blot analysis ofγ-H2AX expression in UMR-106 cells. Cells were treated with Gd-DOTA-BMTP followed by X-ray irradiation (6 Gy). Representative blots (C) and quantitative analysis of protein levels (D) demonstrate significantly increased DNA damage in the combination group compared to controls. E, F Immunofluorescence microscopy visualizing the formation ofγ-H2AX foci (red) within cell nuclei (counterstained with DAPI, blue). Representative images (E) and quantitative analysis (F) are shown. Data are presented as mean ± SD (n = 3). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, ns, no significant Biodistribution of Gd-DOTA-BMTP Building upon the promising in vitro results, we expanded our evaluation to assess the in vivo biodistribution and tumor-targeting capability of Gd-DOTA-BMTP. To preliminarily validate the targeting capability of the core peptide moiety, 131I-labeled BMTP was synthesized. As shown in Fig. 5A, SPECT-CT imaging demonstrated poor intratumoral radiotracer retention at 0.5 h, which was predominantly attributed to tracer extravasation from improper tail vein injection. Radioactivity trapped in the tail was gradually reabsorbed into systemic circulation over time, and tumor accumulation reached its zenith at 4 h post-injection, (Fig. 5A, Supplementary Figures 2A-E). Mirroring these findings, 9.0 T MRI directly visualized Gd-DOTA-BMTP uptake in osteosarcoma tissue, also peaking at approximately 4 h post intravenous injection (Fig. 5B). Next, the biodistribution analysis demonstrated high tumor tissue uptake, with the tumor reaching an average value of 24.80% ID/g, while significantly decreased 24 h post injection (Fig. 5C). To provide a precise quantitative assessment at this optimal time point, ex vivo ICP-MS analysis was performed. the agent exhibited superior specificity, evidenced by favorable tumor-to-normal tissue (T/N > 5:1) and tumor-to-blood (T/B > 3:1) ratios (Fig. 5D).Fig. 5In vivo biodistribution and imaging assessment. A SPECT-CT imaging of orthotopic osteosarcoma-bearing rats following injection of the 131I-labeled BMTP. Representative images at indicated time points confirm the targeting capability of the peptide moiety. B 9.0 T MRI images of the rats before and after Gd-DOTA-BMTP injection, visually verifying the specific accumulation of the probe in tumor tissues. C Quantitative biodistribution profile of Gd-DOTA-BMTP in major organs and tumors measured by inductively coupled plasma mass spectrometry (ICP-MS) at 4 h and 24 h post-intravenous injection. Data are expressed as the percentage of the injected dose per gram of tissue (%ID/g). D Tumor-targeting efficiency analysis showing the tumor-to-normal tissue (T/N) and tumor-to-blood (T/B) ratios derived from the biodistribution data. Data are presented as mean ± SD (n = 5). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, ns, no significant In vivo biodistribution and imaging assessment. A SPECT-CT imaging of orthotopic osteosarcoma-bearing rats following injection of the 131I-labeled BMTP. Representative images at indicated time points confirm the targeting capability of the peptide moiety. B 9.0 T MRI images of the rats before and after Gd-DOTA-BMTP injection, visually verifying the specific accumulation of the probe in tumor tissues. C Quantitative biodistribution profile of Gd-DOTA-BMTP in major organs and tumors measured by inductively coupled plasma mass spectrometry (ICP-MS) at 4 h and 24 h post-intravenous injection. Data are expressed as the percentage of the injected dose per gram of tissue (%ID/g). D Tumor-targeting efficiency analysis showing the tumor-to-normal tissue (T/N) and tumor-to-blood (T/B) ratios derived from the biodistribution data. Data are presented as mean ± SD (n = 5). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, ns, no significant The inhibitory effect of Gd-DOTA-BMTP on osteosarcoma in vivo To ensure precise therapeutic efficacy and minimize potential off-target radiotoxicity to vital organs, a strictly localized tumor-targeted irradiation strategy was implemented (Supplementary Figure S3A). Before evaluating therapeutic efficacy, we first confirmed the in vivo biosafety of the agent. Serum levels of hepatic and renal function indicators, including aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin (TBIL), blood urea nitrogen (BUN), and creatinine (CRE), were quantified prior to injection as well as at 3- and 7-days post-injection. The analysis revealed no statistically significant fluctuations relative to baseline levels, suggesting that Gd-DOTA-BMTP possesses a favorable biosafety profile with negligible acute systemic toxicity (Fig. 6A–E). Having established the safety profile, we proceeded to assess the therapeutic efficacy of Gd-DOTA-BMTP-mediated GdNCT in a mouse model. Tumor volume monitoring in mice was terminated on day 20 due to excessively large tumor volumes in the control group. Throughout this 20-day monitoring period, we found that the group treated with Gd-DOTA-BMTP + Neutron irradiation exhibited the most significant tumor growth suppression compared to all other groups (Fig. 6F, G, Supplementary Figure S3 B-E). Regarding systemic health, the body weight of mice in the combination therapy group remained stable throughout the study. In stark contrast, the control group exhibited significant weight gain (Fig. 6H). It is important to note that this weight gain in the control group was driven by the substantial increase in tumor burden, which outweighed the cachectic effects typically associated with advanced osteosarcoma. Statistical analysis of survival demonstrated a significantly prolonged survival time for the Gd-DOTA-BMTP combined with neutron therapy group within the 20-day monitoring period (Fig. 6I). Collectively, these results provide robust evidence that Gd-DOTA-BMTP combined with neutron irradiation successfully achieves the therapeutic goals of Gd-NCT for osteosarcoma.Fig. 6In vivo biosafety profile and therapeutic efficacy of Gd-DOTA-BMTP-mediated Gd-NCT. A–E In vivo Hepayic and Renal toxicity evaluation. Serum levels of AST, ALT, TBIL,BUN and CRE were measured at 3 and 7 days post-injection to evaluate the hepatic and renal toxicity of Gd-loaded drugs were measured before and at 3 and 7 days post-injection. F Representative photographs of excised tumors from the different experimental groups at the endpoint, visually demonstrating the therapeutic outcome. G Tumor volume growth curves monitoring the progression of osteosarcoma over the 20-day treatment period. H Body weight changes of tumor-bearing mice. I Kaplan–Meier survival curves comparing the life span of mice across different treatment modalities. The combination group shows significantly prolonged survival. Data are presented as mean ± SD (n = 5). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, ns, no significant In vivo biosafety profile and therapeutic efficacy of Gd-DOTA-BMTP-mediated Gd-NCT. A–E In vivo Hepayic and Renal toxicity evaluation. Serum levels of AST, ALT, TBIL,BUN and CRE were measured at 3 and 7 days post-injection to evaluate the hepatic and renal toxicity of Gd-loaded drugs were measured before and at 3 and 7 days post-injection. F Representative photographs of excised tumors from the different experimental groups at the endpoint, visually demonstrating the therapeutic outcome. G Tumor volume growth curves monitoring the progression of osteosarcoma over the 20-day treatment period. H Body weight changes of tumor-bearing mice. I Kaplan–Meier survival curves comparing the life span of mice across different treatment modalities. The combination group shows significantly prolonged survival. Data are presented as mean ± SD (n = 5). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, ns, no significant Discussion Osteosarcoma is the most common primary malignant bone tumor in adolescents. Owing to neoadjuvant chemotherapy, surgery, and adjuvant chemotherapy, the 5-year survival rate of patients with non-metastatic disease is approximately 60–80% (Beird et al. 2022; Smeland et al. 2019). However, the prognosis of patients with metastasis or recurrence is extremely poor, with pulmonary metastasis reducing the 5-year survival rate to well below 20% (Huang et al. 2019; Panez-Toro et al. 2023). In line with the urgent need for novel diagnostic and therapeutic strategies for osteosarcoma, this study focused on IL-11Rα, a cell surface receptor that is highly expressed in both primary osteosarcoma and its metastatic lesions. We designed and synthesized the Gd-DOTA- PMTP polypeptide as a multifunctional targeting probe, and performed a series of in vitro and in vivo experiments to evaluate its potential in osteosarcoma diagnosis and therapy. The concept of boron neutron capture therapy (BNCT) was first proposed by the American biophysicist G. L. Locher in 1936, since then it has emerged as one of the most promising approaches for the treatment of malignant gliomas and recurrent tumors. BNCT is characterized by its binary therapeutic principle: first, tumor cells take up a sufficient concentration of boron carriers; second, neutron beams are used to irradiate the tumor tissues enriched with boron (Barth et al. 2012; He et al. 2021). Currently, BPA is the most widely used tumor-selective boron delivery agent in BNCT. As a boronated amino acid derivative, BPA enters tumor cells via the L-type amino acid transporter 1 (LAT-1) system, which is highly expressed in numerous types of tumor cells (Nomoto et al. 2020; Sun et al. 2026; Zhang et al. 2026). However, BPA suffers from major drawbacks including short intracellular retention time and poor water solubility (Zheng et al. 2025). In comparison, BSH is a carborane-structured compound that typically contains more than 10 boron atoms within its molecular structure, which can effectively increase the boron concentration within tumor tissues while demonstrating higher metabolic stability and lower toxicity. Nevertheless, BSH primarily accumulates through passive diffusion and lacks active tumor-targeting capability. Additionally, BSH is unable to cross the blood–brain barrier (BBB) and can only exert its therapeutic effects in tumor tissues with a disrupted blood–brain barrier (Barth et al. 2018b). The inherent defects in the molecular characteristics of BPA and BSH thus compromised therapeutic efficacy in BNCT. Furthermore, as current boron drugs cannot be visualized by any imaging technique, monitoring drug accumulation in tissues remains challenging. Compared with 10B, 157Gd has the following advantages: it has a higher natural abundance (15.7%); possesses a high thermal neutron capture cross-section, which is the largest among natural nuclides (the thermal neutron capture cross-section of 157Gd is approximately 25,400 barns); and gadolinium carriers can enable in vivo imaging. Owing to these distinct characteristics of Gd, Gd-NCT for tumors has gradually attracted increasing attention in recent years (Ho et al. 2022; Shamsabadi and Baghani 2024). However, the therapeutic efficacy of Gd-NCT and the visualization of drug distribution also critically depends on the degree of gadolinium enrichment within the tumor (Deagostino et al. 2016). Our results showed that supplementation of different concentrations of Gd-DOTA-BMTP to the in vitro culture medium enabled its binding to the cell surface receptor IL-11Rα. Consequently, when IL-11Rα was detected using anti-IL-11Rα antibodies, a higher level of Gd-DOTA-BMTP binding to IL-11Rα resulted in a weaker antibody-detected signal. Administration of Gd-DOTA-BMTP in experimental mice results in high Gd enrichment in the tumor and enables MRI visualization in tumor tissues. Importantly, Gd-DOTA-PMTP exhibited highly favorable tumor-to-normal tissue (T/N) and tumor-to-blood T/B ratios (> 5:1 and > 3:1, respectively), which are expected to help minimize damage to healthy tissues during Gd-NCT. While the tumor uptake achieved nearly 20%ID/g, pharmacokinetic estimations suggest that the absolute drug concentration in the tumor tissue significantly exceeds the absolute number of available IL-11Rα surface receptors. This massive accumulation is therefore unlikely to be driven solely by a 1:1 static surface receptor binding. Instead, we propose that the specific BMTP-IL-11Rα interaction functions primarily as a highly selective tumor-homing initiator. The subsequent high-capacity accumulation is presumed to be driven by dynamic, continuous receptor-mediated endocytosis and receptor recycling, which progressively traps the gadolinium compound intracellularly over time (Bareford and Swaan 2007; Sung et al. 2025). Additionally, the literature has fully demonstrated that the Gd-DOTA scaffold itself can non-specifically enter tumor cells via macropinocytosis, caveolin-dependent endocytosis, and passive diffusion. High concentrations of Gd DOTA based contrast agents in tumors have been commonly observed in clinical and other research studies. For example, as early as 1992, Shih et al. estimated that Gd DOTA could reach a concentration of approximately 2000 μM in brain tumors (Shih and Brugger 1992). One of our previous studies also reported that the prostate cancer targeted probe 157Gd DOTA-PSMA reached a tumor concentration as high as approximately 1183 μM (Xie et al. 2025); meanwhile, the DOTA based AGuIX nanoparticles achieved a concentration of approximately 228 μM in gliomas within 1 h (Rodriguez-Lafrasse et al. 2017). Furthermore, non-specific physiological factors, such as the Enhanced Permeability and Retention (EPR) effect typical of the leaky tumor microenvironment, act synergistically with the active targeting peptide. Together, these dynamic and structural mechanisms achieve and retain the requisite micromolar concentrations of gadolinium necessary for effective neutron capture therapy (Belyaev et al. 2025; Shi et al. 2020). In addition to its diagnostic value, the Gd-DOTA-PMTP polypeptide also showed promising potential for dual-modal therapy, including X-ray sensitization and gadolinium neutron capture therapy (Gd-NCT). While BNCT enables precise tumor cell killing primarily relies on short-range α-particles and recoil lithium nuclei generated intracellularly, Gd-NCT releases Auger electrons and internal conversion electrons with even shorter ranges. Such physical characteristics require gadolinium-based agents to accumulate as close to the nuclear DNA as possible to achieve effective cell killing (Ho et al. 2022; Lee et al. 2022). Notably, binding of the ligand to the IL-11R receptor triggers internalization of the receptor–ligand complex. Traditionally, it is believed that DNA is the target of radiation. However, increasing evidence has demonstrated that DNA is not the sole target of cellular injury. Subcellular structures including the cell membrane, mitochondria, endoplasmic reticulum and lysosomes, as well as cell surface receptors, signaling pathways and the tumor microenvironment, can also be directly affected by external stimuli and independently activate downstream stress responses. These responses can even be triggered prior to DNA damage, and collectively determine cell fate (Ho et al. 2020; Van Delinder et al. 2021). Therefore, a comprehensive understanding of the multi-target and multi-layered injury mechanisms during GdNCT will contribute to a more precise interpretation of cellular effects and the development of novel diagnostic and therapeutic strategies. Furthermore, γ-rays are inevitably generated as byproducts during neutron moderation process and the neutron capture by gadolinium (Gd) also yields additional γ photons. Considering that gadolinium possesses a high mass energy absorption coefficient, exhibit extremely high cross-sections for photoelectric effect and Compton scattering, they efficiently absorb photon energy and produce dense, high-LET secondary electrons that form localized energy deposition hotspots, thereby markedly enhancing DNA damage and cell killing—a phenomenon recognized as the photon radiosensitization effect (Ho et al. 2022; Taupin et al. 2015). Thus, we hypothesized that the interaction between photons and gadolinium may further amplified the overall biological damage. Nevertheless, further in‑depth investigations are still required to clarify the detailed physical and biological mechanisms underlying the tumoricidal activity of Gd‑NCT. In summary, in this study we developed a tumor-targeted agent, Gd-DOTA-BMTP, which showed preliminary potential in targeting tumor tissues. In preclinical models, this agent exhibited a tendency to inhibit osteosarcoma growth and may contribute to improved survival outcomes, suggesting a potential novel strategy that could complement the current clinical management of osteosarcoma. Conclusion In conclusion, this study synthesized the Gd-DOTA-BMTP polypeptide targeting IL-11Rα, which holds the potential of MRI imaging, X-ray sensitization and GdNCT. These results provide a promising new strategy for the diagnosis and treatment of osteosarcoma. However, further research should focus on optimizing the polypeptide structure, verifying its clinical translation potential, and exploring its underlying molecular mechanisms, to promote its application in clinical practice and improve the prognosis of patients with osteosarcoma. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 1